Rilotumumab Biosimilar Monoclonal Antibody (HGF) for Research

Cat No.: GMP-Bios-ab-483

Pre-Made Rilotumumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-483-1mg 1mg 3090

Size： 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Rilotumumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody
INN Name Rilotumumab
TargetHGF
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesAmgen;Astellas Pharma
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedColorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours
Development TechAbgenix XenoMouse



About target - HGF

1. Protein Hepatocyte growth factor

2. Gene HGF

3. Organism Homo sapiens (Human)

Function
Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization.

Caution
Has lost two of the three essential catalytic residues and so probably has no enzymatic activity.